Experientia

, Volume 34, Issue 12, pp 1615–1617 | Cite as

Effect on non-steroidal anti-inflammatory drugs on Moloney sarcoma virus inoculated mice

  • Anna D. Inglot
  • Emilia Oleszak
Pharmacologica

Summary

Chronic administration of phenylbutazone, flufenamic acid and a new, potent non-steroidal anti-inflammatory agent ITF (3-methyl-5-benzoyl-amino-isothiazole-4-carboxy-p-ethoxyphenylamine) to BALB/c mice inoculated with a Moloney sarcoma virus resulted in a stimulation of tumor growth and increased severity of disease. This treatment, however, had no effect on the spontaneous regression of tumors. Indomethacin in a dose of 5.0 or 2.5 mg per kg suppressed the MSV-induced tumor growth, but this effect was apparently connected with the high toxicity of this drug for mice.

Keywords

Toxicity Tumor Growth Sarcoma Indomethacin High Toxicity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J. P. Levy and J. C. Leclerc, in: Advances in Cancer Research, vol. 24, p. 1. Academic Press, New York, San Francisco, London, 1977.Google Scholar
  2. 2.
    G. E. Gillespie and S. W. Russell, Int. J. Cancer21, 94 (1978).PubMedGoogle Scholar
  3. 3.
    S. W. Russell and G. E. Gillespie, J.R.E.S. Soc.22, 159 (1977).Google Scholar
  4. 4.
    J. L. Humes, J. J. Cupo, Jr, and H. R. Strausser, Prostaglandins6, 463 (1974).PubMedGoogle Scholar
  5. 5.
    J. L. Humes and H. R. Strausser, Prostaglandins5, 183 (1974).Google Scholar
  6. 6.
    H. R. Strausser and J. L. Humes, Int. J. Cancer15, 724 (1975).PubMedGoogle Scholar
  7. 7.
    L. M. Pelus and H. R. Strausser, Int. J. Cancer18, 653 (1976).PubMedGoogle Scholar
  8. 8.
    E. Seifter, G. Rettura, S. M. Levenson, M. Appleman and J. Seifter, Life Sci.16, 629 (1975).PubMedGoogle Scholar
  9. 9.
    D. A. Willoughby, C. J. Dunn, P. A. Dieppe and E. C. Huskisson, in Bayer-Symposium VI, Experimental Models of Chronic Inflammatory Diseases, p. 370. Ed. L. E. Glynn and H. D. Schlumberger. Springer-Verlag, Berlin, Heidelberg, New York 1977.Google Scholar
  10. 10.
    D. R. Thomas, G. W. Philpott and M. B. Jaffe, Expl Cell Res.84, 40 (1974).Google Scholar
  11. 11.
    M. G. Santoro, G. W. Philpott and M. B. Jaffe, Nature263, 777 (1976).PubMedGoogle Scholar
  12. 12.
    M. G. Santoro, G. W. Philpott and B. M. Jaffe, Prostaglandins14, 645 (1977).PubMedGoogle Scholar
  13. 13.
    Z. Machoń, A. D. Inglot and E. Wolna, Archs Immunol. Ther. Exper.21, 883 (1973).Google Scholar
  14. 14.
    E. Wolna and A. D. Inglot, Experientia29, 69 (1973).PubMedGoogle Scholar
  15. 15.
    A. D. Inglot, J. gen. Virol.4, 203 (1969).PubMedGoogle Scholar
  16. 16.
    R. J. Flower, R. Gryglewski, K. Herbaczyńska-Cedro and J. R. Vane, Nature, New Biol. 104 (1972).Google Scholar
  17. 17.
    G. C. Easty and D. M. Easty, Cancer Treat. Rev.3, 217 (1976).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1978

Authors and Affiliations

  • Anna D. Inglot
    • 1
  • Emilia Oleszak
    • 1
  1. 1.Laboratory of Tumor Viruses, Department of Tumor Immunology, Institute of Immunology and Experimental TherapyPolish Academy of SciencesWrocŀaw(Poland)

Personalised recommendations